Efficacy of an herbal compound in decreasing steatosis and transaminase activities in non-alcoholic fatty liver disease: Efficacy of an herbal compound in decreasing steatosis and transaminase activities in non-alcoholic fatty liver disease

Seyyed Abbas Zojaji; Hooman Mosannen Mozaffari; Pouya Ghaderi; Faegheh Zojaji; Faegheh Zojaji; Mousa-Al-Reza Hadjzadeh; Monireh Seyfimoqadam; Ahmad Ghorbani

doi:10.1590/s2175-97902022e18825

Authors

Seyyed Abbas Zojaji Department of Education and Research, Army Health Center of Excellence (NEZAJA), Tehran, Iran
Hooman Mosannen Mozaffari Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Pouya Ghaderi Student Research Committee, Faculty of Medicine, Islamic Azad University, Mashhad branch, Mashhad, Iran
Faegheh Zojaji Pain Research Center (PRC), Department of Anesthesiology and Pain Medicine, Rasoul Akram Medical Center, Iran University of Medical Sciences (IUMS), Tehran, Iran
Faegheh Zojaji Pain Research Center (PRC), Department of Anesthesiology and Pain Medicine, Rasoul Akram Medical Center, Iran University of Medical Sciences (IUMS), Tehran, Iran
Mousa-Al-Reza Hadjzadeh Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Monireh Seyfimoqadam Student Research Committee, Faculty of Medicine, Islamic Azad University, Mashhad branch, Mashhad, Iran
Ahmad Ghorbani Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran https://orcid.org/0000-0002-1603-2619

DOI:

https://doi.org/10.1590/s2175-97902022e18825

Keywords:

Anethum graveolens, Citrus, Cynara scolymus, Fatty liver, Portulaca oleracea, Silybum marianum

Abstract

Hepatoprotective effects of many herbal agents have been reported in animal studies and clinical trials. In this study, five hepatoprotective plants with potent antioxidant, anti-inflammatory, and hypolipidemic effects were chosen to prepare a polyherbal compound for managing NAFLD. Sixty patients with NAFLD were randomly divided into treatment and control groups (2:1 ratio). Both group were advised to take healthy diet and exercise. The treatment group also received herbal capsules containing 400 mg of the mixture of Anethum graveolens, Citrus aurantium, Cynara scolymus, Portulaca oleracea, and Silybum marianum (2 capsules, thrice daily, for two months). The liver ultrasound and biochemical markers including the serum lipids, liver enzymes, and glucose were evaluated before starting the study and at the end of the treatment. Thirty patients in the treatment group and sixteen patients in the control group completed the study. The herbal compound significantly decreased the serum level of alanine transaminase (ALT), aspartate transaminase (AST), and total cholesterol. Treatment with the herbal compound significantly improved the grade of the fatty liver, but no significant change was found in the control group. In conclusion, the formulated herbal compound appeared to be effective in biochemical improvement and decreasing the grade of the fatty liver in the patients with NAFLD.

Downloads

Download data is not yet available.

References

Abenavoli L, Aviello G, Capasso R, Milic N, Capasso F. Milk thistle for treatment of nonalcoholic fatty liver disease. Hepat Mon. 2011;11(3):173-7.

Aghazadeh S, Amini R, Yazdanparast R, Ghaffari SH. Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis. Exp Toxicol Pathol. 2011;63(6):569-74.

Baghernya M, Nobili V, Blesso CN, Sahebkar A. Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: a clinical review. Pharmacol Res. 2017;130:213-40.

Bahramikia S, Yazdanparast R. Efficacy of different fractions of Anethum graveolens leaves on serum lipoproteins and serum and liver oxidative status in experimentally induced hypercholesterolaemic rat models. Am J Chin Med. 2009;37(04):685-99.

Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37(S1):81-4.

Ben Hsouna A, Gargouri M, Dhifi W, Saibi W. Antioxidant and hepato-preventive effect of Citrus aurantium extract against carbon tetrachloride-induced hepatotoxicity in rats and characterisation of its bioactive compounds by HPLC-MS. Arch Physiol Biochem. 2018:1-12.

Bundy R, Walker AF, Middleton RW, Wallis C, Simpson HC. Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebo controlled trial. Phytomedicine. 2008;15(9):668-75.

Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-48.

Caldwell SH, Chang CY, Nakamoto RK, Krugner-Higby L. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8(3):595-617.

Chen B, Zhou H, Zhao W, Zhou W, Yuan Q, Yang G. Effects of aqueous extract of Portulaca oleracea L. on oxidative stress and liver, spleen leptin, PARα and FAS mRNA expression in high-fat diet induced mice. Mol Biol Rep. 2012;39(8):7981-8.

Colak E, Ustuner MC, Tekin N, Colak E, Burukoglu D, Degirmenci I, et al. The hepatocurative effects of Cynara scolymus L. leaf extract on carbon tetrachloride-induced oxidative stress and hepatic injury in rats. SpringerPlus. 2016;5(1):216.

El-Sayed M-IK. Effects of Portulaca oleracea L. seeds in treatment of type-2 diabetes mellitus patients as adjunctive and alternative therapy. J Ethnopharmacol. 2011;137(1):643-51.

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908-22.

García-Ruiz C, Fernández-Checa JC. Mitochondrial oxidative stress and antioxidants balance in fatty liver disease. Hepatol Commun. 2018;2(12):1425-39.

Gheflati A, Adelnia E, Nadjarzadeh A. The clinical effects of purslane (Portulaca oleracea) seeds on metabolic profiles in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial. Phytother Res. 2019;33(5):1501-9.

Ghorbani A. Clinical and experimental studies on polyherbal formulations for diabetes: current status and future prospective. J Integ Med. 2014;12(4):336-45.

Hosseini A, Mollazadeh H, Amiri MS, Sadeghnia HR, Ghorbani A. Effects of a standardized extract of Rheum turkestanicum Janischew root on diabetic changes in the kidney, liver and heart of streptozotocin-induced diabetic rats. Biomed Pharmacother. 2017;86:605-11.

Kazemi M. Phenolic profile, antioxidant capacity and anti-inflammatory activity of Anethum graveolens L. essential oil. Nat Prod Res. 2015;29(6):551-3.

Kim G-S, Park HJ, Woo J-H, Kim M-K, Koh P-O, Min W, et al. Citrus aurantium flavonoids inhibit adipogenesis through the Akt signaling pathway in 3T3-L1 cells. BMC Complement Altern Med. 2012;12(1):31.

Mahmoud MF, Hamdan DI, Wink M, El-Shazly AM. Hepatoprotective effect of limonin, a natural limonoid from the seed of Citrus aurantium var. bigaradia, on D-galactosamine-induced liver injury in rats. Naunyn Schmiedebergs Arch Pharmacol. 2014;387(3):251-61.

Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med. 2009;87(7):679.

Mirhosseini M, Baradaran A, Rafieian-Kopaei M. Anethum graveolens and hyperlipidemia: A randomized clinical trial. J Res Med Sci. 2014;19(8):758-61.

Mobasseri M, Payahoo L, Ostadrahimi A, Bishak YK, Jafarabadi MA, Mahluji S. Anethum graveolens supplementation improves insulin sensitivity and lipid abnormality in type 2 diabetic patients. Pharm Sci. 2014;20(2):40-5.

Moradi M-T, Gatreh Samani K, Farrokhi E, Rafieian Koupaei M, Karimi A. The effects of purslane (Portulaca oleracea L.) on serum level of lipids, lipoproteins and paraoxanase 1 (PON1) activity in hypercholesterolemia patients. Life Sci J. 2012;9(4):5548-52.

Nazni P, Vijayakumar TP, Alagianambi P, Amirthaveni M. Hypoglycemic and hypolipidemic effect of Cynara scolymus among selected type 2 diabetic individuals. Pak J Nutr. 2006;5(2):147-51.

Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1):45.

Ou Q, Weng Y, Wang S, Zhao Y, Zhang F, Zhou J, et al. Silybin alleviates hepatic steatosis and fibrosis in NASH mice by inhibiting oxidative stress and involvement with the Nf-κB pathway. Dig Dis Sci. 2018;63(12):3398-408.

Reeves HL, Zaki MY, Day CP. Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD. Dig Dis Sci . 2016;61(5):1234-45.

Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66(1):180-90.

Samarghandian S, Borji A, Farkhondeh T. Attenuation of Oxidative Stress and Inflammation by Portulaca oleracea in Streptozotocin-Induced Diabetic Rats. Evid Based Complement Alternat Med. 2017;22(4):562-6.

Shafiee-Nick R, Ghorbani A, Vafaee Bagheri F, Rakhshandeh H. Chronic administration of a combination of six herbs inhibits the progression of hyperglycemia and decreases serum lipids and aspartate amino transferase activity in diabetic rats. Adv Pharmacol Sci. 2012;2012:789796.

Shen C-Y, Jiang J-G, Huang C-L, Zhu W, Zheng C-Y. Polyphenols from Blossoms of Citrus aurantium L. var. amara Engl. Show Significant Anti-Complement and Anti-Inflammatory Effects. J Agric Food Chem. 2017;65(41):9061-8.

Shi H, Liu X, Tang G, Liu H, Zhang Y, Zhang B, et al. Ethanol extract of Portulaca Oleracea L. reduced the carbon tetrachloride induced liver injury in mice involving enhancement of NF-κB activity. Am J Transl Res. 2014;6(6):746-55.

Speroni E, Cervellati R, Govoni P, Guizzardi S, Renzulli C, Guerra M. Efficacy of different Cynara scolymus preparations on liver complaints. J Ethnopharmacol . 2003;86(2-3):203-11.

Stavropoulos K, Imprialos K, Pittaras A, Faselis C, Narayan P, Kokkinos P. Lifestyle modifications in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Curr Vasc Pharmacol. 2018;16(3):239-45.

Tarantino G, Citro V, Capone D. Nonalcoholic fatty liver disease: a challenge from mechanisms to therapy. J Clin Med. 2020;9(1):15.

Vespasiani-Gentilucci U, Carotti S, Perrone G, Mazzarelli C, Galati G, Onetti-Muda A, et al. Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD. Liver Int . 2015;35(2):569-81.

Zarvandi M, Rakhshandeh H, Abazari M, Shafiee-Nick R, Ghorbani A. Safety and efficacy of a polyherbal formulation for the management of dyslipidemia and hyperglycemia in patients with advanced-stage of type-2 diabetes. Biomed Pharmacother . 2017;89:69-75.

Zeng L, Tang WJ, Yin JJ, Zhou BJ. Signal transductions and nonalcoholic fatty liver: a mini-review. Int J Clin Exp Med. 2014;7(7):1624-31.

Zhu SY, Jiang N, Yang J, Tu J, Zhou Y, Xiao X, et al. Silybum marianum oil attenuates hepatic steatosis and oxidative stress in high fat diet-fed mice. Biomed Pharmacother . 2018;100:191-7.

Efficacy of an herbal compound in decreasing steatosis and transaminase activities in non-alcoholic fatty liver disease